Kiran Pandey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kiran Pandey has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Cristina M. Alberini
Center for Neural Science, New York University, New York, NY, USA
3 shared publications - Shiv Kumar Sharma
National Brain Research Centre
3 shared publications - Xiao-Wen Yu
Center for Neural Science, New York University, New York, United States
2 shared publications Aaron C Katzman
Center for Neural Science, New York University, New York, United States
1 shared publicationAdam Steinmetz
Center for Neural Science, New York University, New York, NY, USA
1 shared publicationChristopher J. Arp
Department of Chemistry, New York University, New York, USA
1 shared publication
Latest Publications
- Open Access
- 30 October 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-17
A prodrug targeting CIM6P/IGF2R enhances memory in healthy mice and reverses deficits in an Angelman syndrome mouse model
Devastating diseases of the central nervous system (CNS), such as neurodevelopmental disorders and neurodegenerative diseases, carry severe neurological symptoms, including cognitive impairment –a decline characterized by learning and memory problems. Currently, no efficacious treatment is available for preventing or treating these diseases; therefore, there is a great unmet need to find novel, effective therapeutics. Previous studies have shown that insulin-like growth factor 2 (IGF2) and mannose 6-phosphate (M6P), two major ligands of the cation-independent M6P/IGF2 receptor (CIM6P/IGF2R), significantly enhance memory and prevent forgetting in healthy animals. Furthermore, they reverse most core symptoms in mouse models of neurodevelopmental disorders, such as Angelman syndrome (AS mice) and autism spectrum disorder, and of neurodegenerative diseases. Starting from the M6P chemical structure, we designed the novel prodrug PMP1. We tested its effects on learning and memory in healthy mice as well as on behavioral deficits in AS mice. We report that both subcutaneous and oral administrations of PMP1 significantly enhance memory strength and persistence in healthy mice. Furthermore, they reverse memory impairments and motor deficits in AS mice. The effect of PMP1 requires the expression of CIM6P/IGF2R in the hippocampus, and the treatment does not elicit any detectable adverse effects. The highest effects were achieved with the same PMP1 maximum effective dose via either route of administration; however, oral administration produced a more prolonged effect. Thus, the novel small-molecule prodrug PMP1, through CIM6P/IGF2R, is a promising therapeutic candidate for Angelman syndrome and an effective memory enhancer.
- 30 October 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-17
Open AccessA prodrug targeting CIM6P/IGF2R enhances memory in healthy mice and reverses deficits in an Angelman syndrome mouse model
Devastating diseases of the central nervous system (CNS), such as neurodevelopmental disorders and neurodegenerative diseases, carry severe neurological symptoms, including cognitive impairment –a decline characterized by learning and memory problems. Currently, no efficacious treatment is available for preventing or treating these diseases; therefore, there is a great unmet need to find novel, effective therapeutics. Previous studies have shown that insulin-like growth factor 2 (IGF2) and mannose 6-phosphate (M6P), two major ligands of the cation-independent M6P/IGF2 receptor (CIM6P/IGF2R), significantly enhance memory and prevent forgetting in healthy animals. Furthermore, they reverse most core symptoms in mouse models of neurodevelopmental disorders, such as Angelman syndrome (AS mice) and autism spectrum disorder, and of neurodegenerative diseases. Starting from the M6P chemical structure, we designed the novel prodrug PMP1. We tested its effects on learning and memory in healthy mice as well as on behavioral deficits in AS mice. We report that both subcutaneous and oral administrations of PMP1 significantly enhance memory strength and persistence in healthy mice. Furthermore, they reverse memory impairments and motor deficits in AS mice. The effect of PMP1 requires the expression of CIM6P/IGF2R in the hippocampus, and the treatment does not elicit any detectable adverse effects. The highest effects were achieved with the same PMP1 maximum effective dose via either route of administration; however, oral administration produced a more prolonged effect. Thus, the novel small-molecule prodrug PMP1, through CIM6P/IGF2R, is a promising therapeutic candidate for Angelman syndrome and an effective memory enhancer.
- Open Access
- 1 June 2021
- Published by Elsevier in Current Research in Pharmacology and Drug Discovery
- Vol. 2, 100033
Autophagy-targeted therapy to modulate age-related diseases: Success, pitfalls, and new directions
- 1 June 2021
- Published by Elsevier in Current Research in Pharmacology and Drug Discovery
- Vol. 2, 100033
Open AccessAutophagy-targeted therapy to modulate age-related diseases: Success, pitfalls, and new directions
- 17 June 2020
- Published by Taylor & Francis in Autophagy
- Vol. 17 (7) , 1614-1635
Autophagy coupled to translation is required for long-term memory
An increase in protein synthesis following learning is a fundamental and evolutionarily conserved mechanism of long-term memory. To maintain homeostasis, this protein synthesis must be counterbalanced by mechanisms such as protein degradation. Recent studies reported that macroautophagy/autophagy, a major protein degradation mechanism, is required for long-term memory formation. However, how learning regulates autophagy and recruits it into long-term memory formation remains to be established. Here, we show that inhibitory avoidance in rats significantly increases the levels of autophagy and lysosomal degradation proteins, including BECN1/beclin 1, LC3-II, SQSTM1/p62 and LAMP1, as well as autophagic flux in the hippocampus. Moreover, pharmacological inhibition or targeted molecular disruption of the learning-induced autophagy impairs long-term memory, leaving short-term memory intact. The increase in autophagy proteins results from active translation of their mRNA and not from changes in their total mRNA levels. Additionally, the induction of autophagy requires the immediate early gene Arc/Arg3.1. Finally, in contrast to classical regulation of autophagy in other systems, we found that the increase in autophagy upon learning is dispensable for the increase in protein synthesis. We conclude that coupling between learning-induced translation and autophagy, rather than translation per se, is an essential mechanism of long-term memory. Abbreviations: AAV: adeno-associated virus; ARC/ARG3.1: activity regulated cytoskeletal-associated protein; ATG: autophagy related; DG: dentate gyrus; GFP: green fluorescent protein; IA: inhibitory avoidance; LAMP1: lysosomal-associated membrane protein 1; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; ODN: oligodeoxynucleotide; qPCR: quantitative polymerase chain reaction; SBI: SBI0206965; SQSTM1/p62: sequestosome 1; SUnSET: surface sensing of translation; TRAP: translating ribosome affinity purification; ULK1: unc-51 like kinase 1
- 17 June 2020
- Published by Taylor & Francis in Autophagy
- Vol. 17 (7) , 1614-1635
Autophagy coupled to translation is required for long-term memory
An increase in protein synthesis following learning is a fundamental and evolutionarily conserved mechanism of long-term memory. To maintain homeostasis, this protein synthesis must be counterbalanced by mechanisms such as protein degradation. Recent studies reported that macroautophagy/autophagy, a major protein degradation mechanism, is required for long-term memory formation. However, how learning regulates autophagy and recruits it into long-term memory formation remains to be established. Here, we show that inhibitory avoidance in rats significantly increases the levels of autophagy and lysosomal degradation proteins, including BECN1/beclin 1, LC3-II, SQSTM1/p62 and LAMP1, as well as autophagic flux in the hippocampus. Moreover, pharmacological inhibition or targeted molecular disruption of the learning-induced autophagy impairs long-term memory, leaving short-term memory intact. The increase in autophagy proteins results from active translation of their mRNA and not from changes in their total mRNA levels. Additionally, the induction of autophagy requires the immediate early gene Arc/Arg3.1. Finally, in contrast to classical regulation of autophagy in other systems, we found that the increase in autophagy upon learning is dispensable for the increase in protein synthesis. We conclude that coupling between learning-induced translation and autophagy, rather than translation per se, is an essential mechanism of long-term memory. Abbreviations: AAV: adeno-associated virus; ARC/ARG3.1: activity regulated cytoskeletal-associated protein; ATG: autophagy related; DG: dentate gyrus; GFP: green fluorescent protein; IA: inhibitory avoidance; LAMP1: lysosomal-associated membrane protein 1; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; ODN: oligodeoxynucleotide; qPCR: quantitative polymerase chain reaction; SBI: SBI0206965; SQSTM1/p62: sequestosome 1; SUnSET: surface sensing of translation; TRAP: translating ribosome affinity purification; ULK1: unc-51 like kinase 1
- Open Access
- 5 May 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
A role for CIM6P/IGF2 receptor in memory consolidation and enhancement
Cation-independent mannose-6-phosphate receptor, also called insulin-like growth factor two receptor (CIM6P/IGF2R), plays important roles in growth and development, but is also extensively expressed in the mature nervous system, particularly in the hippocampus, where its functions are largely unknown. One of its major ligands, IGF2, is critical for long-term memory formation and strengthening. Using CIM6P/IGF2R inhibition in rats and neuron-specific knockdown in mice, here we show that hippocampal CIM6P/IGF2R is necessary for hippocampus-dependent memory consolidation, but dispensable for learning, memory retrieval, and reconsolidation. CIM6P/IGF2R controls the training-induced upregulation of de novo protein synthesis, including increase of Arc, Egr1, and c-Fos proteins, without affecting their mRNA induction. Hippocampal or systemic administration of mannose-6-phosphate, like IGF2, significantly enhances memory retention and persistence in a CIM6P/IGF2R-dependent manner. Thus, hippocampal CIM6P/IGF2R plays a critical role in memory consolidation by controlling the rate of training-regulated protein metabolism and is also a target mechanism for memory enhancement.
- 5 May 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Open AccessA role for CIM6P/IGF2 receptor in memory consolidation and enhancement
Cation-independent mannose-6-phosphate receptor, also called insulin-like growth factor two receptor (CIM6P/IGF2R), plays important roles in growth and development, but is also extensively expressed in the mature nervous system, particularly in the hippocampus, where its functions are largely unknown. One of its major ligands, IGF2, is critical for long-term memory formation and strengthening. Using CIM6P/IGF2R inhibition in rats and neuron-specific knockdown in mice, here we show that hippocampal CIM6P/IGF2R is necessary for hippocampus-dependent memory consolidation, but dispensable for learning, memory retrieval, and reconsolidation. CIM6P/IGF2R controls the training-induced upregulation of de novo protein synthesis, including increase of Arc, Egr1, and c-Fos proteins, without affecting their mRNA induction. Hippocampal or systemic administration of mannose-6-phosphate, like IGF2, significantly enhances memory retention and persistence in a CIM6P/IGF2R-dependent manner. Thus, hippocampal CIM6P/IGF2R plays a critical role in memory consolidation by controlling the rate of training-regulated protein metabolism and is also a target mechanism for memory enhancement.
- 1 May 2020
- Published by Elsevier in Neurobiology of Learning and Memory
- Vol. 171, 107226
Activity- and memory training-induced acetylation of α-tubulin in the hippocampus
- 1 May 2020
- Published by Elsevier in Neurobiology of Learning and Memory
- Vol. 171, 107226
Activity- and memory training-induced acetylation of α-tubulin in the hippocampus
- Open Access
- 15 September 2015
- Published by Cold Spring Harbor Laboratory in Learning & Memory
- Vol. 22 (10) , 514-518
Histone deacetylase inhibition facilitates massed pattern-induced synaptic plasticity and memory
Massed training is less effective for long-term memory formation than the spaced training. The role of acetylation in synaptic plasticity and memory is now well established. However, the role of this important protein modification in synaptic plasticity induced by massed pattern of stimulation or memory induced by massed training is not well understood. Here we show that increasing the level of acetylation enhances long-term potentiation induced by massed pattern of high frequency stimulation. Furthermore, enhancing acetylation level facilitates long-term memory by massed training. Thus, increasing acetylation level facilitates synaptic plasticity and memory by massed patterns.
- 15 September 2015
- Published by Cold Spring Harbor Laboratory in Learning & Memory
- Vol. 22 (10) , 514-518
Open AccessHistone deacetylase inhibition facilitates massed pattern-induced synaptic plasticity and memory
Massed training is less effective for long-term memory formation than the spaced training. The role of acetylation in synaptic plasticity and memory is now well established. However, the role of this important protein modification in synaptic plasticity induced by massed pattern of stimulation or memory induced by massed training is not well understood. Here we show that increasing the level of acetylation enhances long-term potentiation induced by massed pattern of high frequency stimulation. Furthermore, enhancing acetylation level facilitates long-term memory by massed training. Thus, increasing acetylation level facilitates synaptic plasticity and memory by massed patterns.
- Open Access
- 12 March 2011
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 45 (1) , 1-4
Activity-Dependent Acetylation of Alpha Tubulin in the Hippocampus
Posttranslational modifications in proteins play critical roles in synaptic plasticity and memory. In addition, the enduring form of long-term potentiation (LTP) and long-term memory require synthesis of proteins. Some of the mRNAs are present in the dendrites and are locally translated into proteins. Microtubules play critical roles in neuronal transport including the transport of mRNAs from the cell body to the dendrites. Here, we show that KCl depolarization increases acetylation of α-tubulin, a constituent of microtubules, in the CA1 region of the hippocampal slices. Furthermore, activation of N-methyl-d-aspartate receptor, a type of glutamate receptor that plays critical roles in LTP and memory, also enhances α-tubulin acetylation. These results show that acetylation of α-tubulin is modulated in an activity-dependent manner.
- 12 March 2011
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 45 (1) , 1-4
Open AccessActivity-Dependent Acetylation of Alpha Tubulin in the Hippocampus
Posttranslational modifications in proteins play critical roles in synaptic plasticity and memory. In addition, the enduring form of long-term potentiation (LTP) and long-term memory require synthesis of proteins. Some of the mRNAs are present in the dendrites and are locally translated into proteins. Microtubules play critical roles in neuronal transport including the transport of mRNAs from the cell body to the dendrites. Here, we show that KCl depolarization increases acetylation of α-tubulin, a constituent of microtubules, in the CA1 region of the hippocampal slices. Furthermore, activation of N-methyl-d-aspartate receptor, a type of glutamate receptor that plays critical roles in LTP and memory, also enhances α-tubulin acetylation. These results show that acetylation of α-tubulin is modulated in an activity-dependent manner.
- 29 November 2008
- Published by Springer Nature in Investigational New Drugs
- Vol. 27 (6) , 503-516
Regression of Dalton’s lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand
A novel ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide (Ru(II)-CNEB) was found to interact with and inhibit M4-lactate dehydrogenase (M4-LDH), a tumor growth supportive enzyme, at the tissue level. The present article describes modulation of M4-LDH by this compound in a T-cell lymphoma (Dalton’s Lymphoma: DL) vis a vis regression of the tumor in vivo. The compound showed a dose dependent cytotoxicity to DL cells in vitro. When a non toxic dose (10 mg/kg bw i.p.) of Ru(II)-CNEB was administered to DL bearing mice, it also produced a significant decline in DL cell viability in vivo. The DL cells from Ru(II)-CNEB treated DL mice showed a significant decline in the level of M4-LDH with a concomitant release of this protein in the cell free ascitic fluid. A significant increase of nuclear DNA fragmentation in DL cells from Ru(II)-CNEB treated DL mice also coincided with the release of mitochondrial cytochrome c in those DL cells. Importantly, neither blood based biochemical markers of liver damage nor the normal patterns of LDH isozymes in other tissues were affected due to the treatment of DL mice with the compound. These results were also comparable with the effects of cisplatin (an anticancer drug) observed simultaneously on DL mice. The findings suggest that Ru(II)-CNEB is able to regress Dalton’s lymphoma in vivo via declining M4-LDH and inducing mitochondrial dysfunction–apoptosis pathway without producing any toxicity to the normal tissues.
- 29 November 2008
- Published by Springer Nature in Investigational New Drugs
- Vol. 27 (6) , 503-516
Regression of Dalton’s lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand
A novel ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide (Ru(II)-CNEB) was found to interact with and inhibit M4-lactate dehydrogenase (M4-LDH), a tumor growth supportive enzyme, at the tissue level. The present article describes modulation of M4-LDH by this compound in a T-cell lymphoma (Dalton’s Lymphoma: DL) vis a vis regression of the tumor in vivo. The compound showed a dose dependent cytotoxicity to DL cells in vitro. When a non toxic dose (10 mg/kg bw i.p.) of Ru(II)-CNEB was administered to DL bearing mice, it also produced a significant decline in DL cell viability in vivo. The DL cells from Ru(II)-CNEB treated DL mice showed a significant decline in the level of M4-LDH with a concomitant release of this protein in the cell free ascitic fluid. A significant increase of nuclear DNA fragmentation in DL cells from Ru(II)-CNEB treated DL mice also coincided with the release of mitochondrial cytochrome c in those DL cells. Importantly, neither blood based biochemical markers of liver damage nor the normal patterns of LDH isozymes in other tissues were affected due to the treatment of DL mice with the compound. These results were also comparable with the effects of cisplatin (an anticancer drug) observed simultaneously on DL mice. The findings suggest that Ru(II)-CNEB is able to regress Dalton’s lymphoma in vivo via declining M4-LDH and inducing mitochondrial dysfunction–apoptosis pathway without producing any toxicity to the normal tissues.